메뉴 건너뛰기




Volumn 14, Issue 1, 2009, Pages 67-69

Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis-evidence and controversy

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SORAFENIB;

EID: 61449098645     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0281     Document Type: Note
Times cited : (26)

References (14)
  • 1
    • 33644747449 scopus 로고    scopus 로고
    • BAY 43-9006 inhibition of oncogenic RET mutants
    • Carlomagno F, Anaganti S, Guida T et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006;98:326-334.
    • (2006) J Natl Cancer Inst , vol.98 , pp. 326-334
    • Carlomagno, F.1    Anaganti, S.2    Guida, T.3
  • 2
    • 4944249117 scopus 로고    scopus 로고
    • BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
    • Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-7109.
    • (2004) Cancer Res , vol.64 , pp. 7099-7109
    • Wilhelm, S.M.1    Carter, C.2    Tang, L.3
  • 3
    • 33749017926 scopus 로고    scopus 로고
    • Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
    • Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006:24: 4293-4300.
    • (2006) J Clin Oncol , vol.24 , pp. 4293-4300
    • Abou-Alfa, G.K.1    Schwartz, L.2    Ricci, S.3
  • 4
    • 47949116252 scopus 로고    scopus 로고
    • Sorafenib in advanced hepatocellular carcinoma
    • Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378 -390.
    • (2008) N Engl J Med , vol.359 , pp. 378-390
    • Llovet, J.M.1    Ricci, S.2    Mazzaferro, V.3
  • 5
    • 57749189578 scopus 로고    scopus 로고
    • Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial
    • Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
    • (2009) Lancet Oncol , vol.10 , pp. 25-34
    • Cheng, A.L.1    Kang, Y.K.2    Chen, Z.3
  • 6
    • 28844490547 scopus 로고    scopus 로고
    • Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies
    • D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. J Hepatol 2006;44:217-231.
    • (2006) J Hepatol , vol.44 , pp. 217-231
    • D'Amico, G.1    Garcia-Tsao, G.2    Pagliaro, L.3
  • 7
    • 59149096464 scopus 로고    scopus 로고
    • Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis?
    • 217s
    • Abou-Alfa GK, Amadori D, Santoro A et al. Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis? J Clin Oncol 2008;26:(15 suppl):217s.
    • (2008) J Clin Oncol , vol.26 , Issue.15 SUPPL.
    • Abou-Alfa, G.K.1    Amadori, D.2    Santoro, A.3
  • 8
    • 58049217937 scopus 로고    scopus 로고
    • Efficacy and tolerability of single agent sorafenib in poor risk advanced hepatocellular carcinoma patients
    • 656s
    • Yau T, Chan P, Ng K et al. Efficacy and tolerability of single agent sorafenib in poor risk advanced hepatocellular carcinoma patients. J Clin Oncol 2008;26:(15 suppl):656s.
    • (2008) J Clin Oncol , vol.26 , Issue.15 SUPPL.
    • Yau, T.1    Chan, P.2    Ng, K.3
  • 9
    • 61449256583 scopus 로고    scopus 로고
    • Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis
    • Pinter M, Sieghart W, Graziadei I et al. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. The Oncologist 2009;14:70-76.
    • (2009) The Oncologist , vol.14 , pp. 70-76
    • Pinter, M.1    Sieghart, W.2    Graziadei, I.3
  • 10
    • 61449095992 scopus 로고    scopus 로고
    • Nexavar®tablets (Bayer HealthCare Pharmaceuticals). In: 2009 Physician's Desk Reference (PDR), 63rd Edition. Toronto, Canada: Thomson, 2009:784-790.
    • Nexavar®tablets (Bayer HealthCare Pharmaceuticals). In: 2009 Physician's Desk Reference (PDR), 63rd Edition. Toronto, Canada: Thomson, 2009:784-790.
  • 11
    • 33645648696 scopus 로고    scopus 로고
    • Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics
    • Lathia C, Lettieri J, Cihon F et al. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol 2006;57:685-692.
    • (2006) Cancer Chemother Pharmacol , vol.57 , pp. 685-692
    • Lathia, C.1    Lettieri, J.2    Cihon, F.3
  • 12
    • 38049019119 scopus 로고    scopus 로고
    • Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: A review of clinical trials
    • Takimoto CH, Awada A. Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: A review of clinical trials. Cancer Chemother Pharmacol 2008;61:535-548.
    • (2008) Cancer Chemother Pharmacol , vol.61 , pp. 535-548
    • Takimoto, C.H.1    Awada, A.2
  • 13
    • 38049021509 scopus 로고    scopus 로고
    • Pharmacokinetic (PK) and phase I study of sorafenib (S) for solid tumors and hematologic malignancies in patients with hepatic or renal dysfunction (HD or RD): CALGB 60301
    • 147s
    • Miller AA, Murry DJ, Owzar K et al. Pharmacokinetic (PK) and phase I study of sorafenib (S) for solid tumors and hematologic malignancies in patients with hepatic or renal dysfunction (HD or RD): CALGB 60301. J Clin Oncol 2007;25(18 suppl):147s.
    • (2007) J Clin Oncol , vol.25 , Issue.18 SUPPL.
    • Miller, A.A.1    Murry, D.J.2    Owzar, K.3
  • 14
    • 36949033865 scopus 로고    scopus 로고
    • Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma
    • Furuse J, Ishii H, Nakachi K et al. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sei 2008;99:159-165.
    • (2008) Cancer Sei , vol.99 , pp. 159-165
    • Furuse, J.1    Ishii, H.2    Nakachi, K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.